Welcome to our dedicated page for Caribou Biosciences SEC filings (Ticker: CRBU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Caribou Biosciences, Inc. (Nasdaq: CRBU) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including Forms 10-K, 10-Q, 8-K, and other Exchange Act reports. As a clinical-stage CRISPR genome-editing biopharmaceutical company, Caribou uses these filings to report on its financial condition, clinical development progress, and key corporate events.
Current and periodic reports such as Forms 10-Q and 10-K contain management’s discussion of operating results, research and development spending on allogeneic CAR-T programs like vispacabtagene regedleucel (vispa-cel; formerly CB-010) and CB-011, and information about licensing and collaboration revenue. These filings also describe risk factors associated with developing allogeneic CAR-T cell therapies, the company’s dependence on clinical trial outcomes, and its capital resources.
Form 8-K filings are especially relevant for tracking material events at Caribou. Recent 8-Ks have furnished press releases announcing quarterly financial results and business updates, preliminary cash and investment balances, and detailed clinical data from the ANTLER phase 1 trial of vispa-cel and the CaMMouflage phase 1 trial of CB-011. An 8-K dated June 18, 2025, also documents Nasdaq’s notice that Caribou regained compliance with the minimum bid price requirement under Listing Rule 5450(a)(1).
Investors interested in regulatory strategy and designations can use these filings to review discussions of RMAT, Fast Track, and Orphan Drug designations for vispa-cel and CB-011, as well as the company’s description of a planned randomized, controlled pivotal phase 3 trial for vispa-cel in second-line large B cell lymphoma.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify important disclosures on clinical data, cash runway, and Nasdaq listing status. Real-time updates from EDGAR, along with access to current and historical 8-Ks and other reports, support deeper analysis of CRBU’s regulatory and financial history.
Caribou Biosciences reported that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to CB-011, its allogeneic anti-BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma. The designation is based on phase 1 CaMMouflage trial dose-escalation data in a 12-patient BCMA-naïve cohort, which showed a 92% overall response rate, a 75% complete response or better rate, and 91% minimal residual disease negativity at the recommended expansion dose. Forty-eight patients have been treated in dose escalation, and the ongoing dose expansion is testing a 450x106 CAR-T cell dose in both BCMA-naïve and BCMA-exposed patients, with additional data expected in 2026. CB-011 has shown a manageable safety profile, with common treatment-emergent adverse events including neutropenia, anemia, thrombocytopenia, infections, and cytokine release syndrome.
Caribou Biosciences, Inc. is a clinical-stage genome-editing company using its proprietary CRISPR chRDNA technology to develop off‑the‑shelf CAR‑T cell therapies for blood cancers. As of June 30, 2025, non‑affiliate equity market value was $112.5 million, and 96,637,202 common shares were outstanding as of February 27, 2026.
The company’s two lead allogeneic CAR‑T programs are vispa‑cel for relapsed or refractory B‑cell non‑Hodgkin lymphoma and CB‑011 for relapsed or refractory multiple myeloma. Vispa‑cel has U.S. FDA RMAT, fast track, and orphan drug designations, while CB‑011 has fast track and orphan designations.
On April 24, 2025, Caribou announced a strategic pipeline prioritization, discontinuing its GALLOP vispa‑cel lupus trial, the AMpLify CB‑012 trial in acute myeloid leukemia, and preclinical research, and reducing its workforce by approximately 32%. Caribou also highlights a $25.0 million equity investment by Pfizer and multiple licensing agreements supporting its intellectual property portfolio.
Caribou Biosciences reported fourth quarter and full year 2025 results while highlighting progress in its allogeneic CAR-T pipeline. Licensing and collaboration revenue was $3.9 million in Q4 2025 and $11.2 million for 2025, up from $2.1 million and $10.0 million in 2024, mainly from prior IP licenses.
Research and development expenses fell to $109.4 million for 2025 from $130.2 million in 2024, and general and administrative expenses declined to $37.9 million from $46.5 million, reflecting workforce reductions and pipeline prioritization. The company recorded $21.3 million of non-recurring, non-cash impairment charges in 2025.
GAAP net loss was $26.5 million (or $0.28 per share) in Q4 2025 and $148.1 million (or $1.59 per share) for 2025. Non-GAAP net loss for 2025, excluding impairment charges, was $126.8 million (or $1.36 per share). Caribou held $142.8 million in cash, cash equivalents, and marketable securities as of December 31, 2025 and expects this to fund its current operating plan, including CB-011 dose expansion and certain start-up activities for a planned vispa-cel pivotal trial, into 2H 2027.
Caribou Biosciences, Inc. Chief Technology Officer Timothy P. Kelly reported an open-market sale of 6,228 shares of common stock at $1.93 per share. After this February 25, 2026 transaction, he directly owns 73,125 shares of Caribou Biosciences common stock.
Caribou Biosciences filed a notice relating to the proposed sale of 6,938 common shares tied to the vesting of restricted stock units on 02/20/2026.
The shares were granted as part of the issuer's equity compensation plan and are reported through a Form 144 filing for proposed resale on the NASDAQ.
Caribou Biosciences, Inc. submitted a Rule 144 notice relating to 6,938 common shares associated with vesting restricted stock units granted under its equity compensation plan. The filing lists dates 02/20/2026 (vesting/grant) and 02/24/2026 (filing) and identifies NASDAQ as the market.
Timothy Kelly reported proposed sales of common stock via a Form 144. The filing lists 6228 shares of restricted common stock dated 02/20/2026 and shows 3147 common shares sold during the past three months on 02/24/2026 with an amount of 6162.14. The transaction is reported in connection with Nasdaq-listed securities.
Caribou Biosciences Chief Technology Officer Timothy P. Kelly reported a mix of equity awards and a small tax-related share sale. He received 45,000 restricted stock units that vest in four equal annual installments beginning on February 20, 2027, settling in stock within 30 days after each vesting date.
He was also granted an option to buy 202,500 shares of common stock, vesting monthly so the option is fully vested by February 20, 2030. Separately, 3,147 shares of common stock were sold at $1.96 per share under a mandatory sell‑to‑cover policy to satisfy tax withholding when previously granted RSUs vested, and this did not represent a discretionary trade. After these transactions, Kelly directly holds 79,353 shares of common stock and 202,500 option shares.
Caribou Biosciences Chief Legal Officer Barbara G. McClung reported both equity grants and a small share sale. She received a grant of options to purchase 202,500 shares of common stock and a separate grant of 45,000 restricted stock units, both awarded on February 20, 2026.
The options vest in equal monthly installments over 48 months until February 20, 2030, and the RSUs vest in four equal annual installments beginning February 20, 2027, contingent on continued service. On February 24, 2026, 6,938 shares were sold at $1.96 per share solely to cover tax withholding on previously vested RSUs under an existing Rule 10b5-1 sell-to-cover plan, leaving her with 481,564 common shares directly owned.
Caribou Biosciences Chief Business Officer Ruhi Ahmad Khan reported a mix of equity grants and a small tax-related share sale. On February 24, 2026, Khan sold 6,938 shares of common stock at $1.96 per share in an open-market transaction, leaving 104,998 shares held directly. A footnote explains this was a sell-to-cover trade executed under a Rule 10b5-1 plan solely to satisfy tax withholding on vesting RSUs, not a discretionary sale.
On February 20, 2026, Khan received a grant of 45,000 restricted stock units that vest in four equal annual installments beginning on February 20, 2027, with shares delivered within 30 days after each vesting date. On the same date, Khan was granted options for 202,500 shares of common stock, vesting monthly over 48 months so that the option is fully vested by February 20, 2030, contingent on continued service.